The Vector Core has been and will continue to be a critical component of the Dendritic Cell Program. The Vector Core will function within the framework of the Program as a dynamic resource that can provide state-of- the-art viral vector technology as well as develop novel vectors. The major emphasis of the Vector Core is also developing adenovirus vectors for gene delivery and is developing expression vectors for use in liposome and particle-mediated gene transduction. The role of the Vector Core is also developing mediated gene transduction. The role of the Vector Core in the Dendritic Cell Program will be to construct and provide vectors expressing the appropriate genes for the proposed experiment. In addition, the core will provide cell lines, packaging lines, plasmids, plasmids- coated gold beads, and protocols as needed to each of the projects working on dendritic cells. The Core also will work with the projects and Core B to optimize viral and non-viral gene delivery to dendritic cells. Furthermore, the Core will provide technical assistance and training to individuals in the use of viral and non-viral vectors for gene transfer to dendritic cells as needed. An additional part of the Vector Core is the Fermentation Laboratory where clinical grade plasmid DNA can be prepared for human applications.
The specific aims of the Vector Core are: 1. To provide each investigator with either viral or non-viral vectors, expressing the required therapeutic gene, that are appropriate for their proposed experiments. 2. To develop improved viral and non-viral vectors for more efficient gene transfer to dendritic cells with higher and/or regulated gene expression. 3. To help develop methods for efficient gene delivery to mouse and human dendritic cells. 4. To provide technical assistance and protocols to each of the projects in the use of viral and non-viral gene delivery systems for delivery to dendritic cells. 5. To produce clinical grade DNA for human applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-04
Application #
6414828
Study Section
Project Start
2001-01-01
Project End
2001-12-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications